Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NEK2 | P51955 | 1/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11947867 | 0.85 | TSHR (0.41) | NEK2OPRD1TSHR | |
| SCHEMBL12880918 | 0.84 | DRD4 (0.38) | — | |
| SCHEMBL14252370 | 0.76 | — | — | |
| SCHEMBL14422013 | 0.76 | — | — | |
| SCHEMBL1930118 | 0.75 | — | — | |
| SCHEMBL6050504 | 0.72 | DRD4 (0.31) | — | |
| SCHEMBL12563431 | 0.72 | GRIN2D (0.44) | CHRM2 | |
| SCHEMBL12880916 | 0.71 | — | — | |
| SCHEMBL1886832 | 0.69 | — | — | |
| SCHEMBL1929396 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3867238-B1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2020081848-A1 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS | ARRAY BIOPHARMA INC. (US) | 2020-04-23 | — | — | WO | disclosed |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. | 2010-10-28 | — | — | US | disclosed |
| US-7271165-B2 | Rifamycin analogs and uses thereof | ACTIVBIOTICS, INC. (US) | 2007-09-18 | — | — | US | disclosed |
| US-20070142392-A1 | Uses of rifamycins | ACTIVBIOTICS, INC. (US) | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142392-A1 | Uses of rifamycins | TNF, TLR6, IL6 | NEK2 3456/4885OPRD1 2983/4885TSHR 2603/4885 |
| US-20100273765-A1 | Rifamycin analogs and uses thereof | RIF1, HDAC5, AADAC | NEK2 1757/4885OPRD1 3678/4885TSHR 2329/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.